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Summary A retrospective, population-based study was undertaken to determine variations in the management
of women aged less than 50 years with primary breast cancer in different hospital settings and the influence of
these variations on survival. A total of 1757 women who were resident in the South East Thames Health
Region aged less than 50 years at the time of diagnosis of breast cancer and who presented during a 5 year
period (January 1984 to December 1988) were recorded by the Thames Cancer Registry. The hospitals at which
primary surgery was undertaken were categorised as teaching or non-teaching hospitals. The non-teaching
hospitals were grouped according to the mean number of patients treated annually during the study period
(4 2, 3-9, > 10 each year). The following factors were compared between these groups: age, extent of disease,
tumour morphology, extent of primary surgery (mastectomy vs less than mastectomy), use of axillary surgery
(any vs none) and use of systemic adjuvant therapy. Survival rates for the different groups were compared.
Registration rates did not differ significantly between health districts. A total of 1485 (85%) women underwent
surgery in over 90 different hospitals. In 1324 (86%) of these cases the surgery was undertaken in a total of 42
NHS hospitals within SE Thames Health Region or in seven teaching hospitals in adjacent regions.
Mastectomy rates decreased from 52% in 1984 to 28% in 1988 (P<0.0001), but were consistently higher in
teaching hospitals (P=0.01). The use of any form of axillary surgery decreased from 49% to 36% over the 5
year period (P=0.003), with significantly lower rates of axillary surgery being performed in non-teaching
hospitals (P<0.0001). The proportion of cases recorded as having non-specific morphology was higher in non-
teaching than in teaching hospitals (P<0.0001). On multivariate analysis survival was significantly (P<0.001)
influenced by stage and tumour histology. Among patients who underwent surgery, the type of hospital in
which this was undertaken did not appear to influence survival significantly. This analysis of routine cancer
registry data indicates that patients were widely dispersed in a large number of different hospitals and that
there were marked variations in practice according to the type of hospital to which patients presented. The
treatments provided were frequently at variance with those recommended at a consensus conference held
during the study period, particularly in relation to the use of axillary surgery and adjuvant systemic therapy.
The way in which services are currently provided may hamper the delivery of appropriate management and
comprehensive support. These data thus have implications for the purchasing and provision of services for this
common condition.
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Breast cancer is the commonest female malignancy in the
UK, with approximately 25 000 new cases annually, ofwhom
about 15 000 will ultimately die from the disease (OPCS,
1994). Although mainly affecting women over the age of 50
years, 20-25% of cases occur below this age (Thames Cancer
Registry, 1993; Chouillet et al., 1994). Breast cancer is the
leading cause of death in women aged 35-49 years in the
UK, accounting for about 20% of all deaths in this age
group (OPCS, 1993). The UK national breast cancer
screening programme involves women over the age of 50
years only. Thus earlier detection of symptomatic disease and
more effective management are necessary if survival is to be
improved in younger women.
Treatment of breast cancer has changed considerably in
the past 20 years. Whereas a radical or modified radical
mastectomy used to be the standard treatment, it is now clear
that in appropriate cases breast-conserving treatment achieves
equivalent long-term survival rates (Veronesi et al., 1981;
Sarrazin et al., 1983; Fisher et al., 1985; Van Dongen et al.,
1991; Lichter et al., 1992). Furthermore, in the past 10 years
it has become increasingly apparent that systemic adjuvant
therapy following surgery leads to a reduction in recurrence
rates and mortality (Early Breast Cancer Trialists' Colla-
borative Group, 1992).
In October 1986 a consensus statement on the treatment of
operable breast cancer was published (King's Fund Forum,
1986). Topics included the appropriate assessment of women
suspected of having breast cancer; the best forms of initial
local treatment and systemic treatment; the advantages and
disadvantages of different degrees of patient participation in
treatment decisions, and how services for treating breast
cancer should be organised most effectively.
Against this background we analysed the primary
treatment given to all women resident in the South East
Thames Health Region who were diagnosed as having
invasive breast cancer aged less than 50 years between
January 1984 and December 1988. This period was chosen as
a time of likely change in management of breast cancer,
following publication of early trial results concerning the
efficacy of breast-conserving therapy and the possible benefits
of systemic adjuvant therapy. Selection of this period also
gave adequate follow-up time to assess the outcome of such
management.
Methods
The Thames Cancer Registry (TCR) supplied anonymised
data for all patients aged less than 50 years registered with
breast cancer for the period 1 January 1984 to 31 December
1988 who were resident in the South East Thames Regional
Health Authority (SETHRA). Each patient record comprised
35 data items collected by registry peripatetic clerks who visit
the hospitals in the four Thames regions and collate data on
regional residents treated in other regions. Age and district of
residence were known for all patients.
The Registry supplied the surgical data classified into 20
groups. For the purposes of this analysis these were grouped
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as mastectomy or less than mastectomy and axillary surgery
(any vs none). This simple classification of surgical
procedures was adopted because mastectomy (simple,
modified radical or radical) can usually be differentiated
from a range of breast conserving procedures (e.g. local
excision, or quadrantectomy) from the operation note
recorded by the surgeon. Equally it is usually clear from
the operation note and pathology reports whether any
axillary surgery has been undertaken. The extent of axillary
surgery (sampling or clearance) may be more difficult to
ascertain accurately. Only the first two operations undergone
by each patient were included in the analysis. When patients
had more than one operation, the combined effect of these
operations was classified as above. The hospital at which
primary surgery was undertaken was recorded in almost all
cases, the only exception to this being a small number of
cases for whom the hospital was recorded as being 'private'.
The hospitals at which primary surgery was undertaken have
been grouped as teaching or non-teaching and by their
geographical location (within or outside SETRHA). Non-
teaching hospitals were further subdivided according to the
total number of patients in this age group who underwent
breast cancer surgery over the 5 year period (up to 10; 11-49
and 50 or more). In rare cases when surgery was undertaken
at two separate hospitals, the first hospital was used for the
purpose of this analysis.
Extent of disease is recorded by TCR using nine different
'categories'. For the purposes of this analysis, these have been
simplified to three groups - local (1-2); local plus nodes (3-
4); metastatic (5 -9). Tumour histology was coded to 37
distinct ICD-0 morphology codes. In this study these have
been grouped as ductal carcinoma; other specific histological
types (e.g. lobular, tubular and medullary carcinoma) and
non-specific diagnoses (e.g. 'malignancy not otherwise
specified' or 'adenocarcinoma').
The use of radiotherapy is recorded, as is the use of
systemic therapy (endocrine treatment and/or chemotherapy)
given in the first 6 months after diagnosis. It was assumed
that patients who underwent primary surgery and subse-
quently received systemic therapy within a period of 6
months had this as adjuvant treatment. In most cases (92%)
systemic treatment commenced within 3 months of first
surgery, making it unlikely that this was being given for overt
relapse.
Statistics
Age-specific registration rates were calculated for females
aged 35-49 resident in each district, using OPCS population
estimates for the years 1984-88. The data set was compiled
by TCR in December 1992. All deaths occurring before
October 1991 were recorded through linkage to national
death certification. All patients who were not recorded as
having died by October 1991 were assumed to be alive at that
time, unless status at the date of last record was missing. A
small number of patients (55/1757, 3%) were identified
through death certification only and have been excluded
from the survival analyses.
The proportional hazards model was used to estimate the
influence of explanatory variables on survival. Hazard ratios
relative to a baseline category were estimated for the defined
categories of district of residence, extent of disease,
histological subgroup, age and hospital type. The overall
significance of the association of the variable with survival
was tested using the likelihood ratio. The Cox proportional
hazards model was fitted using the BMDP package (Dixon,
1990) and statistical comparisons between groups were made
using the chi-square test.
Results
A total of 1812 women aged less than 50 years with breast
cancer had been registered by TCR in the 15 districts of
SETRHA during the period 1 January 1984 to 31 December
1988. Thirty women with in situ cancer only and 12 with a
diagnosis of lymphoma, sarcoma or melanoma (of the skin)
of the breast have been excluded. The current status (alive or
dead) of a further 13 patients was missing at the last record,
leaving a total of 1757 (97%) cases for further analysis.
Demographic data
Forty-seven (3%) of the 1757 women were aged less than 30
years; 121 (7%) 30-34 years, 341 (19%) 35-39 years and
1248 (71%) 40-49 years. There was no significant change in
the registration rate over the 5 year study period (18% of
cases being registered for 1984 and 20% for 1988).
The number of registrations in each district of residence
over the 5 year period ranged from 78 to 163. The
registration rates varied from 1.42 to 2.14 per 10 000 women
in the age range 35-49 years in each district per annum
(P=0.07). For the three inner London districts, the incidence
was 1.80, compared with 1.76 for the four outer London
districts and 1.94 for the eight non-metropolitan districts
(P=0.26).
Primary surgery
A total of 1485 (84.5%) of the 1757 patients were recorded as
having undergone at least one surgical procedure related to
the breast and/or axillary lymph nodes. These operations
were performed in at least 90 different hospitals. Of all the
women, 396 (27%) underwent surgery at a teaching hospital,
three of which are located in SETRHA and seven in adjacent
regions. More than 50 women underwent breast surgery in
each of the three teaching hospitals within SETRHA and the
other seven teaching hospitals are known from Thames
Cancer Registry data (not shown) to have comparably large
breast cancer practices. A further 928 (62%) women
underwent surgery in a total of 39 non-teaching hospitals
within SETRHA (Table I). The remaining 161 (11%) patients
were treated surgically in a total of 14 NHS non-teaching
hospitals outside SE Thames (23 patients) or in private
institutions (138 patients). The 1324 women shown in Table
I, who were treated in SETRHA hospitals or in teaching
hospitals in adjacent regions, form the basis of the
subsequent detailed analysis of treatment patterns (group A).
The type of hospital to which the 1324 patients were
initially referred depended to a large extent on their district
of residence. Eight of the 15 districts within SE Thames are
located more than 20 miles from any teaching hospital. Only
32 of 742 (4.3%) women from these districts underwent
primary surgery at a teaching hospital. A further four
districts have no teaching hospital within the district, but
are within 20 miles of one. Primary surgery was undertaken
in a teaching hospital in 179/352 (51%) of cases from these
districts. One district has both a teaching hospital and a non-
teaching hospital and the remaining two districts have a
teaching hospital only. Referrals to a teaching hospital for
residents of these three districts were 41/83 (49%), 75/78
(96%), and 69/69 (100%) respectively.
The extent of surgery varied considerably between
hospitals, with major changes in practice being observed
over the 5 year period. The proportion of women undergoing
mastectomy is shown in Table I, with higher mastectomy
rates in teaching hospitals (42%) than non-teaching hospitals
(35%, P=0.01). Mastectomy was undertaken in 52% of
patients who presented in 1984, compared with only 28% of
patients who presented in 1988 (P<0.0001). The changes in
practice in teaching and non-teaching hospitals over time are
shown in Table II. In both teaching hospitals and in non-
teaching hospitals the decrease in mastectomy rates over time
was significant (P=0.02 and P<0.0001 respectively).
Only 560 (42%) ofthe women who underwent surgery had
any form of operation on the axillary lymph nodes recorded
by the Registry. The proportion of women treated in teaching
hospitals who underwent axillary surgery (65%) was twice
that for women in non-teaching hospitals (32.5%,
P<0.0001). The proportion of women undergoing anyBreast cancer in SE Thames region
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Table I Surgical treatment according to type of hospital
Number of Per cent of Axillary
n patients total Mastectomy surgery
Teaching
hospitals 10 396 (30%) 167 (42%) 258 (65%)
Non-teaching
hospitals
(>50 patients) 5 376 (28%) 105 (28%) 111 (30%)
Non-teaching
hospitals
(11-49 patients) 15 454 (34%) 185 (41%) 163 (36%)
Non-teaching
hospitals
(10 patients) 19 98 (7%) 33 (34%) 28 (29%)
Total 49 1324 490 (37%) 560 (42%)
axillary surgery decreased significantly over the study period
from 114/231 (49%) in 1984 to 94/262 (36%) in 1988
(P=0.003). Axillary surgery rates remained constant over
time within teaching hospitals, but decreased markedly in
non-teaching hospitals (Table III).
The possibility was considered that variations in casemix
between patients referred to teaching and non-teaching
hospitals might account for the observed differences in
surgical practice. This might apply particularly to residents
of districts located an intermediate distance from a teaching
hospital, for whom referral practice varied most widely.
Further analyses were therefore undertaken, excluding the
352 residents of these districts. The mastectomy rate over the
5 year period in this subgroup was 42% for patients treated
at teaching hospitals, compared with 32% for those treated at
non-teaching hospitals (P<0.004). Similarly, 59% ofteaching
hospital patients underwent axillary surgery compared with
29% of non-teaching hospital patients (P<0.0001).
Staging and tumour histology
Extent of disease was recorded for 1556 (89%) patients, of
whom 1161 (75%) were classified as having local disease, 298
(19%) local disease plus nodes and 97 (6%) metastatic
disease at presentation. Extent of disease according to
hospital type is shown in Table IV for the 1324 patients in
group A. Patients treated in teaching hospitals were recorded
as having 'local disease plus nodes' significantly more
frequently than others (P<0.0001). Whether this reflects a
true difference in casemix or simply reflects the greater use of
axillary surgery in teaching hospitals and therefore more
complete staging information is uncertain.
Tumour histology was recorded as non-specific in 608 of
the 1757 cases (35%). Of these 'non-specific' diagnoses, 183
were made among the 272 patients whose tumours were not
excised and were therefore presumably made on needle
Table II Mastectomy rates: changes over time
Teaching Non-teaching Total
1984 39/72 (54%) 82/159 (52%) 121/231 (52%)
1985 44/103 (43%) 76/180 (42%) 120/283 (42%)
1986 37/82 (44%) 63/184 (34%) 100/266 (38%)
1987 24/75 (32%) 53/207 (26%) 77/282 (27%)
1988 24/64 (38%) 49/198 (25%) 73/262 (28%)
Total 168/396 (42%) 323/928 (35%) 491/1324 (37%)
Decrease in mastectomy rates over time (test for trend): Teaching
hospitals, x2 =5.6 on 1 d.f., P=0.02; non-teaching hospitals, x2 =38.5
on 1 d.f., P<0.0001.
biopsy specimens. Among the 1324 patients in group A,
784 (59%) had ductal carcinoma, 195 (15%) had another
specific diagnosis and 345 (26%) had a non-specific diagnosis.
The rate of non-specific diagnosis was 17% in teaching
hospitals, 20% at non-teaching hospitals treating more than
50 patients each and 38% in hospitals treating a smaller
number of patients (P<0.001).
Radiotherapy
Radiotherapy was given to the breast and/or lymph nodes in
1116 (64%) of the 1757 patients. Within group A 170 (35%)
of the 490 patients who underwent mastectomy also had
radiotherapy. Of note was the fact that 149 (18%) of the 834
who underwent breast-conserving therapy were not recorded
as having any radiotherapy.
Systemic adjuvant therapy
A total of 555 (42%) of the 1324 patients in group A received
some form of adjuvant systemic therapy. Details of the
adjuvant therapy administered are shown in Table V.
Table HI Axillary surgery: changes over time
Teaching Non-teaching Total
1984 48/72 (67%) 66/159 (42%) 114/231 (49%)
1985 66/103 (64%) 65/180 (36%) 131/283 (46%)
1986 55/82 (67%) 64/184 (35%) 119/266 (45%)
1987 48/75 (64%) 54/207 (26%) 102/282 (36%)
1988 41/64 (64%) 53/198 (27%) 94/262 (36%)
Total 258/396 (65%) 302/928 (32.5%) 560/1324 (42%)
Change in axillary surgery rates over time (test for trend): Teaching
hospitals, X2=0.07 on 1 d.f., P=0.79; non-teaching hospitals,
X2= 12.8 on 1 d.f., P<0.0003.
Table IV Extent of disease according to hospital type
Teaching Non-teaching Total
Local 247 (69%) 737 (82%) 984 (78%)
Local and nodes 94 (26%) 134 (15%) 228 (18%)
Metastatic 17 (5%) 29 (3%) 46 (4%)
Unknown 38 - 28 - 66 (-)
Total 396 928 1324
x2=25.3 on 2 d.f.; P<0.000l.
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Table V Adjuvant therapy-according to hospital of first surgery
Teaching Non-teaching Total
Chemotherapy 46 (12%) 49 (5%) 95 (7%)
Hormonal therapy 89 (22%) 336 (36%) 425 (32%)
Combined therapy 10 (3%) 25 (3%) 35 (3%)
Surgery only 251 (63%) 518 (56%) 769 (58%)
Total 396 928 1324
X2=34.6 on 3 d.f.; P<0.0001.
Survival
A total of 556 (32%) ofthe women were known to be dead at
the end of follow-up (October 1991). The proportions of
patients known to be dead according to year of registration
were 42% for 1984, 36% for 1985, 38% for 1986, 26% for
1987 and 19% for 1988.
The influence of demographic factors (age and district of
residence) and tumour-related factors (extent of disease and
histology) on survival was assessed for the whole patient
group (n = 1702), excluding those diagnosed through death
certification only (n = 55). Both extent of disease (P<0.0001)
and histology (P<0.0001) were highly significant predictors
of survival, patients with localised disease and those with
specific histological subtypes of breast cancer having the best
outcome (Table VI). Neither age (P=0.13) nor district of
residence (P=0.14) influenced survival significantly, though
considerable differences in hazard ratios were observed
between the districts with highest and lowest mortality (1.00
and 1.98 respectively).
A second analysis was undertaken restricted to the 1324
patients in group A. Demographic factors (age and district of
residence) and type of hospital were included in the model.
As differences in extent of disease and histological coding
between teaching and non-teaching hospitals might be due to
differences in surgical procedure and pathological expertise
(see above), these factors were not included in this model.
Among these surgically treated cases only age had a
significant influence on survival, with patients under 35
years faring worse (P =0.02).
Discussion
Most reports on the management and outcome of patients
with breast cancer in the UK relate to women treated in
specialist centres or those treated in multicentre trials. One
previous report compared the treatment and outcome of
women managed at two centres where radiotherapy and
chemotherapy were available, one in an urban teaching
district, the other a rural non-teaching district (Basnett et al.,
1992). That study, involving a total of 999 women, 235 of
whom were aged 50 years or less, appeared to show
significantly worse survival for women treated in the non-
teaching district (odds of death 1.46, P=0.0009). The
authors, however, advised that this finding should be treated
with caution and recommended that cancer registries should
be used as a tool for audit. A recent study from the Thames
Cancer Registry examined the treatment given to 334
residents of the four Thames regions who were diagnosed
in early 1990, 86 of whom were aged less than 50 years
(Chouillet et al., 1994). However, differences in management
between treatment centres were not analysed and survival
data were not shown.
In the current study, covering a defined geographical
population, we have examined the treatment and outcome for
women under 50 years. We were particularly interested in this
age group as there is a strong rationale for undertaking
axillary surgery in order to obtain prognostic information
that may be of importance in giving advice related to the use
of adjuvant systemic therapy. To the best of our knowledge
this study is the first in which the number of patients treated
Table VI Survival analysis-Cox proportional hazards model
Hazard
Variable ratio 95% CI X2 df. P-value
(a) All patients (n=1702)
District of residence
Lowest hazard 1.00
Highest hazard 1.98 (1.19, 3.29) 19.8 14 0.14
Extent of disease
Local 1.00
Local and nodes 2.26 (1.82, 2.80)
Metastatic 6.81 (5.23, 8.88)
Unknown 1.42 (1.02, 1.98) 169.2 3 0.00001
Histology
Specific 1.00
Ductal 1.62 (1.17, 2.26)
Non-specific 2.13 (1.52, 2.99) 22.7 2 0.00001
Age
Under 35 1.00
35 and over 0.80 (0.60, 1.06) 2.3 1 0.13
(b) Surgical cases only (n= 1324)
District of residence
Lowest hazard 1.00
Highest hazard 2.66 (1.37, 5.17) 17.5 14 0.23
Hospital type
Non-teaching 1.00
Teaching 1.27 (0.93, 1.74) 2.2 1 0.14
Age
Under 35 1.00
35 and over 0.67 (0.49, 0.93) 5.3 1 0.02in different centres, and the type of hospital (teaching, non-
teaching or private) has been assessed in relation to survival.
This may be of particular relevance if the recent
recommendations of the Expert Advisory Group on Cancer
to the Chief Medical Officers of England and Wales are to be
implemented (Expert Advisory Group on Cancer, 1995). That
report recommends the establishment of a network of 'cancer
centres' and 'cancer units' throughout the UK, and that a
hospital should seek to function as a cancer unit only if the
volume of work related to each cancer site is sufficient to
maintain subspecialisation.
Although it is impossible to be certain of the completeness
of ascertainment of cases by TCR, estimates from the
Registry place completeness for breast cancer at all ages at
over 86% of all cases diagnosed (J Bullard, personal
communication). There is no reason to believe that there
are any inherent biases in the completeness of reporting from
different hospitals. The completeness of the treatment data is
also good for most items. The quality of registry data is,
however, dependent on the quality of hospital case records.
The study by Chouillet et al. (1994) showed that retrospective
reconstruction of staging (I-IV) is only possible in about
50% of cases even after detailed scrutiny of case records. We
therefore used the staging classification adopted by Thames
Cancer Registry, which is based on pathological information
when available and clinical data for the remainder. This
undoubtedly underestimates the true incidence of node
positivity, which might be expected to be approximately
50%, compared with 19% classified as having 'local disease
and nodes' in the current study. We also adopted a simple
classification of treatments to minimise errors due to
differences in recording of surgical procedures by surgeons.
Women in the UK with suspected breast cancer are
normally referred to a general surgeon for assessment. As
shown in this study, breast surgery was undertaken in 42
NHS hospitals in SETRHA during the 5 year study period.
The short study period of only a few weeks covered in the
report by Chouillet et al. (1994) may have led to a
considerable underestimate of the total number of hospitals
managing primary breast cancer (reported as 81 for the four
Thames regions) as those hospitals managing only a few cases
annually may well not have diagnosed any patients during
that period.
In the current study almost 90% of the patients who
underwent surgery received this in NHS hospitals within the
region or in teaching hospitals in adjacent regions. Of these,
58% received their surgical treatment in a teaching hospital
or in one of five non-teaching hospitals with a relatively large
breast cancer practice (i.e. on average more than ten cases in
this age group per annum). A further 34% of patients
underwent surgery in a total of 15 hospitals, each of which
treated between two and ten patients in this age group
annually. The remaining 7% of the patient population
underwent surgery in a total of 19 hospitals, each of which
dealt with an average of less than two such patients annually.
Although these figures apply only to residents of SE Thames
region, it is unlikely that significant cross boundary flows
occurred with patients being referred to SE Thames hospitals
other than to teaching hospitals.
Referral to a teaching hospital or to a non-teaching
hospital depended largely on geographical access. Almost all
patients living in districts situated more than 20 miles from a
teaching hospital underwent primary surgery in a non-
teaching hospital. Conversely, the large majority of women
living in the districts served directly by a teaching hospital
underwent treatment there. For women resident in the four
districts situated an intermediate distance from a teaching
hospital it is possible that referral may have been affected by
casemix (e.g. tumour size). However, it seems more likely that
individual GPs in these districts selectively refer the majority
of women with breast problems to one preferred centre. In
any case, when women in these four districts were excluded
from the analysis, the differences in surgical practice observed
between hospital types remained highly significant.
Does this wide dispersal of patients between hospitals
Breast cancer in SE Thames region
MA Richards et a! a
755
affect either the care that the receive or their long-term
survival? The King's Fund onsensus statement (1986)
concluded that although ther is no evidence that survival
is any better in specialist its than in general hospitals, a
strong case can be made for grouping together the services
for women with breast cancer. This was based on the
assumption that surgeons with no special interest in breast
cancer are less likely to be aware of trial results and other
advances, and may be less skilled in appreciating the
woman's need for information and psychological support. It
must have been difficult, if not impossible, for the 34
hospitals identified in this study as managing only a small
number of patients each year to provide care in the setting of
a multidisciplinary breast clinic. The King's Fund consensus
statement argues that such a clinic should involve a surgeon,
pathologist, trained nurse counsellor, and a radiotherapist
and/or medical oncologist. In each district a psychiatrist
should be attached to the breast team. This multidisciplinary
approach would help to ensure that appropriate treatments
are considered for every patient. It would also serve to meet
the women's information, psychological and practical needs
on a more comprehensive basis. The advantages of multi-
disciplinary care within specialist breast clinics have recently
been stressed in a report from the British Breast Group
(1994).
In keeping with the assertion made in the consensus
statement, we observed no difference in survival according to
the number of patients treated in a particular hospital.
However, meaningful survival comparisons require know-
ledge ofthe casemix in different hospitals that is not available
in the TCR data. The teaching hospitals appeared to have a
lower proportion (69%) of localised cases than district
general hospitals (79%), but this may reflect either the use
of more axillary nodal surgery in teaching hospitals, or more
advanced cases being referred there. The Registry is now
collecting data on tumour size and the number of nodes
sampled in order to provide more accurate information on
casemix. The influence of tumour size on outcome has been
clearly demonstrated in a study involving almost 25 000
women with breast cancer (Carter et al., 1989).
As far as the assessment of women with breast cancer is
concerned, involvement of axillary lymph nodes is well
recognised as the most important determinant of prognosis,
followed by histological type and grade (Carter et al., 1989;
Bloom and Richardson, 1957; O'Reilly et al., 1990).
Information regarding axillary nodal status may be of
particular importance in women under 50 years, as this
may be used in deciding whether to recommend adjuvant
chemotherapy. The consensus statement clearly recommended
that axillary nodes should be sampled at the time of breast
surgery. In practice, only 42% of women with operable
breast cancer in this study were recorded as having any form
of axillary surgery. Axillary surgery was performed less
frequently in district general hospitals and the proportion of
patients receiving such assessment actually fell after the
publication of the consensus statement. The less frequent use
of axillary surgery in non-teaching hospitals is in direct
contrast to the findings reported by Basnett et al. for the
same age group (1992). The low overall rate of axillary
surgery is, however, similar to that reported by other studies
(Chouillet et al., 1994; Basnett et al., 1992). It should be
noted that some underrecording of axillary surgery by TCR
may have affected this study, as this has been observed when
Registry data are compared with case records for audit
purposes (AM Chouillet, personal communication). We have
no reason, however, to believe that this would affect the
trends noted over time or differences observed between
hospital types. The low rates of axillary surgery in this and
other studies do, however, call into question the reliability of
information gained from questionnaire surveys as a guide to
what occurs in clinical practice (Morris et al., 1989, 1992).
For example, in reply to a questionnaire in 1992, 77% of
surgeons recommended either axillary dissection or sampling
(Morris et al., 1992).
In addition to the inadequate assessment of nodal status,Bantcc hin
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this study has also shown that the prognostic information
related to histological type is also less frequently available
among patients treated in hospitals with a smaller breast
cancer practice. Information related to tumour grade was not
available for this study. However, the larger proportion of
cases with non-specific morphology codes in hospitals
treating smaller numbers of patients suggests that this
prognostic information is also frequently not available.
It has now been demonstrated in several randomised
controlled trials that, for appropriately selected cases, long-
term survival following breast conserving therapy is
equivalent to that observed following mastectomy. Prelimin-
ary reports from two of these studies (Veronesi et al., 1981;
Sarrazin et al., 1983) were published before the start of our
study period and a major report from the USA was published
in 1985 (Fisher et al., 1985). The proportion of women under
50 years in SETRHA receiving breast conservation therapy of
any form increased during the study period from 48% to
72% of operable cases, with higher rates consistently being
observed in non-teaching hospitals. Without knowledge of
tumour size or multifocality, it is difficult to judge whether
such treatment was appropriate. Nor is it possible to assess
what choice was offered to individual patients. However, it is
clear that surgeons working outside teaching hospitals have
adopted the use of breast conservation therapy more rapidly
and for a larger proportion of their patients than have their
teaching hospital colleagues.
Knowledge of the reduction in relapse and death rates
achievable in women under 50 years with systemic adjuvant
therapy increased markedly during the 1980s, with several
reports being published by 1985 (Rossi et al., 1981; Fisher et
al., 1983; Anonymous, 1984; Baum et al., 1983, 1985). The
King's Fund consensus statement made it clear that (i)
combination chemotherapy reduces the death rate in node-
positive patients aged less than 50 years; (ii) destroying
ovarian function had a similar effect on mortality; (iii) there
was some evidence of a reduced relapse rate with tamoxifen.
In practice, the use of adjuvant chemotherapy was very
limited in SE Thames at least up to 1988. Indeed, most
treated cases were confined to one hospital in which trials of
chemotherapy were being conducted. Tamoxifen was,
however, quite widely used, particularly in district general
hospitals. It should be noted that several hospitals in SE
Thames participated in the NATO and CRC adjuvant
therapy studies between 1977 and 1985 and physicians were
thus familiar with the use of tamoxifen (Baum et al., 1983;
CRC Adjuvant Breast Trial Working Party, 1988). Patients
in SE Thames may thus have benefited from the administra-
tion of tamoxifen, even though the objective evidence
supporting its effect on survival in premenopausal women
has only become clear-cut more recently (Scottish Cancer
Trials Office, 1987; Early Breast Cancer Trialists' Collabora-
tive Group, 1992). The findings of the current study can be
compared with those for 383 patients of all ages treated at
the Middlesex and University College Hospitals in 1986
(McCarthy and Bore, 1991). As in our study, the authors
noted that a significant number of patients received
lumpectomy without radiotherapy. Chemotherapy was given
to 27% and tamoxifen to 26% of women under 50 years
(compared with 12% and 22% respectively in our teaching
hospital group).
In conclusion, this study has demonstrated that primary
treatment for women aged less than 50 years is provided in a
multitude of different hospitals, the majority of which treat
only very limited numbers of patients. Treatment given to
patients varied significantly between hospitals. While this has
not been shown to have an adverse effect on survival, a high
proportion ofwomen managed outside teaching hospitals are
receiving a form of surgical management that has never been
validated by randomised controlled trials. The lack of
pathological information related to nodal status almost
certainly leads to inappropriate recommendations regarding
adjuvant treatment.
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